WHO 2022 AML Classification Mapper

Now defined by specific cytogenetic abnormalities or somatic mutations in genes such as ASXL1, BCOR, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2. Morphological dysplasia alone is no longer sufficient for this category.

Molecular classification is the primary driver for targeted therapy selection (e.g., FLT3 inhibitors, IDH1/2 inhibitors, or CPX-351 for AML-MR).

Developed through an international consensus of hematopathologists and clinicians to replace the 2016 4th Revised Edition.